Introducing the Fall 2018 FAST Companies
Seven life science startups, vetted and selected by a distinguished review panel, will join CLSI’s Fall 2018 Fellows All-Star Team (FAST) Advisory Program. The Fall 2018 FAST cohort includes: CellFE, developing a unique device to efficiently deliver gene-editing molecules into cells, while preserving cell viability; Mantra Bio, an exosome therapeutics company focused on harnessing naturally occurring human exosomes to develop safe, ultra-targeted therapies to combat intractable diseases; Methodologie Labs, a simulation-based medical education company developing a training method that utilizes a proprietary pulsatile perfusion pump to simulate cardiac physiology for use in cadavers for use in medical schools, residency programs and the military; Pinpoint Science, developing low-cost handheld diagnostics to detect viral, bacterial and fungal pathogens in seconds; YourChoice Therapeutics, developing novel non-hormonal contraceptives. In addition, two companies will join the Fall FAST cohort via the CARB-X track, through which companies targeting drug-resistant bacteria and in scope for CARB-X funding can participate in the FAST program: Centauri Therapeutics of Sandwich, England, is developing novel immunotherapeutics to treat life-threatening diseases using their proprietary ‘Alphamer’ platform technology; and Linnaeus Bioscience of San Diego is developing novel compounds to treat drug resistant bacterial infections.
Each company founder will be paired with a team of 10 to 12 advisors who will meet with them over 12 weeks of group advisory sessions. These meetings culminate in a final FAST Showcase in December to a broad audience of industry professionals, entrepreneurs and potential investors.
Starting its sixth year, FAST was developed to help some of the most innovative young life science companies FAST-track their way to funding and success. FAST’s 56 company graduates have received over 6200 volunteer advisory hours valued at over $1,400,000, have collectively raised over $660 million and have created 258 new jobs since their participation in FAST.
The FAST program draws on a high-level team of serial entrepreneurs, researchers, investors and business advisors with expertise in clinical development, regulatory, reimbursement, relevant technical R&D, finance, marketing and business development. The teams provide FAST entrepreneurs with intensive team review and coaching to perfect their business model and develop a compelling commercialization strategy.